Medpace Earnings: Elevated Cancellations Continue to Pose Challenges for Near-Term Growth

Medpace reported weak first-quarter results. Despite revenue increasing 9% to $559 million compared with the first quarter last year, net new business awards were $500 million in the quarter, representing a nearly 19% decrease from the prior-year period. This resulted in a weak net book/bill ratio of 0.9 times, and backlog decreased 2.1% from the prior-year period. The bookings shortfall is due to more cautious client decisions, pipeline cancellations, and delays in project starts. Medpace's customer base is unique from other large, publicly traded contract research organizations; it primarily consists of small biopharma companies (about 80% of revenue), which poses elevated risks in a challenging macroeconomic environment due to funding constraints.